development pact news from FierceBiotech
News
Merck turns to Ranbaxy for $100M R&D effort
India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy, which received an undisclosed upfront payment, says Read more...
NicOx shares plunge on Pfizer trial failure
Shares of France's NicOx tumbled 38 percent after Pfizer announced that it would not advance their Read more...
Funds from non-profit groups flow to biotech R&D
Epix Pharmaceuticals said this morning that its development pact with the Cystic Fibrosis Foundation has mushroomed into a $50 million deal, adding $37.7 million to the $12 million already provided Read more...
Wyeth kills off Solvay pact
Following bifeprunox's FDA rejection in August, Wyeth has opted out of its development deal with Solvay. Read more...
Icagen gains $10M in equity sale to Pfizer
Icagen has triggered an option to sell $10 million worth of stock to Pfizer. That's on top of the $5 million Read more...
Analysis: OncoMed deal puts a premium on preclinical
OncoMed's $1.4 billion antibody development pact with GlaxoSmithKline is dissected by the San Read more...
SPOTLIGHT: Crucell forges pact with Sanofi
Crucell stands to gain $112 million in a new development pact with Sanofi Pasteur, which wants to use its antibodies for a rabies vaccine. Read more...
GSK, Santaris ink $700M development deal
In a deal that starts small but has a big upside, Santaris Pharma has forged a development pact with GlaxoSmithKline to develop new antiviral meds. Denmark's Santaris gets $3 million up front and a Read more...
Merck halts leukemia trials after adverse event
Vertex says that Merck suspended two clinical trials of the leukemia drug MK-0457 after one of the patients in the study developed a heart condition--QTc prolongation--caused by a disruption in the Read more...
NicOx pushes new naproxen version for arthritis pain
The Wall Street Journal reports on the progress that NicOx is making advancing a new version of naproxen for relieving arthritis pain. The French biotech is looking for a marketing partner for the Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight